BIOMAT Database Logo BIOMAT Database Logo

Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998

K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Department of Internal Medicine-Nephrology, Universitätsklinikum Charité, Humboldt University, Berlin, Germany.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus rescue therapy for renal transplant rejection.
August 1996, Transplantation proceedings,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation.
April 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus for rescue therapy in refractory renal allograft rejection.
November 2000, Transplantation proceedings,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus rescue therapy in patients with rejection and long-term dialysis after kidney transplantation.
January 1998, Clinical nephrology,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus rescue therapy for renal allograft rejection--five-year experience.
January 1997, Transplantation,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus rescue therapy for children with acute renal transplant rejection.
December 2001, Pediatric nephrology (Berlin, Germany),
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group.
December 1996, Transplantation proceedings,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Sirolimus rescue therapy for refractory rejection in renal transplantation.
June 2001, Transplantation,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus for rescue of refractory renal allograft rejection.
June 1998, Transplantation proceedings,
K Budde, and L Fritsche, and S Smettan, and B Schönberger, and S A Loening, and I Mai, and S Bauer, and J Waiser, and H H Neumayer
Tacrolimus rescue therapy for renal allograft rejection refractory to cyclosporine-based immunosuppression.
April 1996, Transplantation proceedings,
Copied contents to your clipboard!